Loading clinical trials...
Loading clinical trials...
This is a pilot study (phase 1 clinical trial) to evaluate the safety and tolerability of phenylbutyrate in IBM. In this open label study, 10 patients with sporadic inclusion body myositis will be tre...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
University of Kansas Medical Center
NCT00017914 · Dermatomyositis, Polymyositis, and more
NCT07374107 · IBM, IIM, and more
NCT06479863 · Sporadic Inclusion Body Myositis (sIBM), Idiopathic Inflammatory Myopathies
NCT06536166 · Inclusion Body Myositis, Sporadic
NCT04789070 · Inclusion Body Myositis
University of Kansas Medical Center
Kansas City, Kansas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions